Cancer patients with diabetes face a dual challenge: managing the toxic effects of chemotherapy while keeping blood glucose levels in a safe range. Hyperglycemia—generally defined as fasting blood glucose above 126 mg/dL or random readings above 200 mg/dL—is common during cancer treatment and can lead to infections, delayed wound healing, longer hospital stays, and even interruptions in chemotherapy. Understanding the underlying mechanisms is the first step toward prevention.

How Chemotherapy Drugs Disrupt Glucose Homeostasis

Several chemotherapeutic agents directly or indirectly raise blood sugar. For instance, platinum-based drugs like cisplatin can cause nephrotoxicity, reducing renal clearance of insulin and oral hypoglycemics such as metformin and sulfonylureas. This accumulation can paradoxically increase both hyperglycemia risk (via altered metabolism) and hypoglycemia risk if doses aren’t adjusted. Other agents, including asparaginase and certain tyrosine kinase inhibitors, have been linked to impaired insulin secretion or peripheral insulin resistance. Additionally, the physiologic stress of cancer itself—along with treatment-related inflammation and infection—triggers release of counter-regulatory hormones like cortisol and epinephrine, which promote gluconeogenesis and elevate blood glucose. Patients should be aware that any sudden rise in glucose could signal an underlying infection, which requires immediate medical attention.

The Impact of Corticosteroids on Blood Sugar

Many chemotherapy protocols include corticosteroids such as dexamethasone or prednisone to prevent allergic reactions, control nausea, and manage pain. These drugs are potent hyperglycemic agents: they increase hepatic glucose production, reduce peripheral glucose uptake, and impair insulin secretion. Most patients experience a glucose spike within two to six hours of steroid administration, and the effect can persist for 24 hours or longer depending on the dose and steroid type. Managing steroid-induced hyperglycemia often requires preemptive insulin adjustments—typically with NPH insulin timed to coincide with peak steroid effect—or the use of supplementary rapid-acting insulin before meals. The American Diabetes Association provides evidence-based guidelines for adjusting insulin regimens during corticosteroid therapy.

Chemotherapy–Drug Interactions with Diabetes Medications

Chemotherapy can alter the pharmacokinetics of oral hypoglycemic agents and insulin. For example, drugs that cause renal impairment (e.g., cisplatin, ifosfamide) may lead to accumulation of metformin, raising the risk of lactic acidosis. Sulfonylureas like glipizide can accumulate and cause prolonged hypoglycemia when kidney function declines. Conversely, certain tyrosine kinase inhibitors may potentiate the action of insulin, requiring dose reductions. Patients on SGLT2 inhibitors (e.g., empagliflozin) need to be closely monitored during illness because of the risk of euglycemic diabetic ketoacidosis, which can occur without extreme hyperglycemia. The National Comprehensive Cancer Network offers guidance on medication management for patients with comorbidities during cancer treatment. Never adjust diabetes medications without consulting your oncology team and endocrinologist; this coordination is essential to prevent both hyperglycemia and hypoglycemia.

Comprehensive Strategies to Prevent Hyperglycemia During Chemotherapy

Preventing hyperglycemia requires an integrated approach that combines frequent monitoring, tailored nutrition, physical activity, stress reduction, and careful medication adjustment. Below are evidence-based strategies that patients and providers can implement together.

Blood Glucose Monitoring: The Foundation of Glycemic Control

Frequent glucose monitoring is non-negotiable during chemotherapy. For most patients, testing four to six times daily—including fasting, pre-meal, post-meal, and bedtime—provides the data needed to spot trends and intervene early. Continuous glucose monitors (CGMs) offer real-time glucose levels, trend arrows, and alarms for hyperglycemia and hypoglycemia. During chemotherapy, when appetite and insulin sensitivity can change rapidly, CGM data can be lifesaving. Many insurance plans now cover CGMs for patients with type 1 or type 2 diabetes on insulin, and some plans extend coverage to those with high glucose variability. Keeping a log (paper or app) that records glucose values, meal times, carbohydrate counts, medication doses, and symptoms helps both patient and clinician make informed adjustments. For example, a pattern of post-steroid hyperglycemia at 2:00 PM every day can be addressed with a scheduled insulin dose at that time.

Nutritional Strategies for Stable Blood Sugar

Dietary consistency is key to preventing both hyperglycemia and hypoglycemia during chemotherapy. Work with a registered dietitian who understands oncology nutrition to create a flexible meal plan that accommodates treatment side effects like nausea, taste changes, and early satiety. General principles include:

  • Eat small, frequent meals every three to four hours to avoid large glucose swings. A typical day might include three small meals and two to three snacks.
  • Choose low–glycemic-index carbohydrates such as whole oats, quinoa, lentils, barley, and non-starchy vegetables (broccoli, spinach, peppers). These release glucose slowly and help maintain stable levels.
  • Pair carbohydrates with protein and fat at every eating occasion. Protein (lean meats, eggs, tofu, Greek yogurt) and healthy fats (avocado, nuts, seeds, olive oil) slow digestion and blunt post-meal glucose spikes.
  • Manage nausea with strategic choices: If oral intake is challenging, try bland, easy-to-digest foods like crackers, rice, applesauce, or clear soups. Ginger tea or peppermint can soothe the stomach without significantly affecting blood sugar.
  • Stay hydrated with sugar-free fluids. Dehydration can concentrate blood glucose and worsen hyperglycemia. Water, herbal teas, and sugar-free electrolyte drinks are best. Avoid fruit juices, regular soda, and sweetened coffees.

Patients should never skip meals, even if not hungry. Keep backup snacks handy—a small handful of almonds, a cheese stick, or a piece of whole fruit—to help maintain blood sugar stability. The Academy of Nutrition and Dietetics has a helpful guide on eating well during cancer treatment.

Physical Activity as a Blood Sugar Regulator

Moderate exercise improves insulin sensitivity and helps lower blood glucose. However, chemotherapy can cause fatigue, neuropathy, anemia, and other side effects that limit activity. Always consult your oncology team before starting or resuming an exercise program. For most patients, gentle activities such as walking, yoga, tai chi, or stationary cycling can be safely performed. Key precautions:

  • Start slowly: Begin with 5–10 minute sessions and gradually increase to 20–30 minutes as tolerated, most days of the week.
  • Check blood glucose before and after exercise: If pre-exercise glucose is <100 mg/dL, eat a small carbohydrate snack. If it is >250 mg/dL and you have ketones (from a urine or blood test), avoid intense activity—exercise can actually raise glucose further in this state.
  • Carry a fast-acting carbohydrate source (glucose tablets, juice box, or hard candy) in case hypoglycemia occurs during or after exercise.
  • Stay hydrated: Drink water before, during, and after exercise.
  • Listen to your body: On days when fatigue or nausea is severe, rest is appropriate. Even five minutes of gentle stretching can have psychological benefits.

Stress Reduction Techniques to Lower Cortisol

Psychological stress activates the hypothalamic-pituitary-adrenal axis, elevating cortisol and blood glucose. Chronic stress is common in cancer patients, and it can directly worsen glycemic control. Simple, evidence-based practices can help:

  • Mindfulness meditation: Even five minutes of focused breathing or body scan meditation can lower perceived stress and reduce blood glucose. Many apps (e.g., Headspace, Calm) offer guided sessions.
  • Gentle movement: Walking, yoga, or tai chi not only improve glucose uptake but also provide a mental break from treatment-related worries.
  • Social support: Joining a support group—either in person or online—for cancer patients with diabetes can reduce feelings of isolation and provide practical tips from peers. Many cancer centers now offer these groups.
  • Professional counseling: If anxiety or depression interferes with self-care, ask your oncology team for a referral to a mental health professional who specializes in chronic illness.

Medication Adjustments: A Collaborative Effort

Diabetes medications often need to be modified during chemotherapy. Patients should never change doses on their own; instead, work with a team that includes the oncologist, endocrinologist, and clinical pharmacist. Common adjustments include:

  • Insulin regimen modifications: Basal insulin (long-acting) may need to be reduced if appetite is poor, while bolus insulin (rapid-acting) may need to be timed to coincide with steroid peaks. Some patients benefit from supplemental correction doses based on pre-meal glucose levels.
  • Oral hypoglycemic agent changes: Metformin is generally safe but may be held before contrast imaging or surgery. Sulfonylureas often require dose reduction if kidney function declines. SGLT2 inhibitors may be stopped during periods of vomiting or dehydration to avoid diabetic ketoacidosis.
  • Steroid-induced hyperglycemia management: A common strategy is to add a fixed dose of NPH insulin at the time of steroid administration to counteract the predictable glucose rise. For example, if dexamethasone is given at 8:00 AM, 0.1–0.2 units/kg of NPH may be given subcutaneously as a one-time dose.

Keep an updated medication list (including over-the-counter drugs and supplements) and share it with every provider. Some supplements can affect blood glucose or interact with chemotherapy, so do not take any without approval.

Practical Tips for Patients and Caregivers

Prepare for Treatment Days

On the morning of chemotherapy, eat a balanced breakfast with protein and a small amount of complex carbohydrate to maintain stable glucose through the infusion. Let the infusion nurse know you have diabetes and ask what the center’s protocol is for managing hyperglycemia or hypoglycemia during treatment. Bring your glucose meter, CGM device, and fast-acting carbohydrate so you can self-manage. Many centers now have a standardized order set for glucose checks and correction doses during infusion.

Recognize and Respond to Glycemic Emergencies

Know the warning signs of hyperglycemia (excessive thirst, frequent urination, blurred vision, fatigue, dry skin) and hypoglycemia (shakiness, sweating, confusion, hunger, irritability). For moderate hyperglycemia (glucose 180–300 mg/dL), drink extra water and take your prescribed medications. Glucose above 400 mg/dL accompanied by nausea, vomiting, or confusion requires immediate medical evaluation—it could indicate diabetic ketoacidosis. For hypoglycemia, follow the 15–15 rule: consume 15 grams of fast-acting carbohydrate (4 ounces of fruit juice, 3–4 glucose tablets, or 6–8 hard candies), wait 15 minutes, and recheck. If still low, repeat. If you are unable to swallow safely, a caregiver should administer glucagon (injectable or nasal spray). Educate family members on this process before a crisis occurs.

Prevent and Treat Infections Quickly

Even minor infections (urinary tract, respiratory, skin) can cause dramatic glucose elevations and increase the risk of chemotherapy delays. Report any signs of infection—fever, chills, redness, pain, or unusual discharge—to your oncology nurse immediately. Patients with diabetes who develop fever should be evaluated for infection and may require antibiotic treatment. Good hand hygiene, avoiding crowded places during neutropenic nadirs, and staying up to date on vaccinations (including flu and pneumonia) can reduce risk. The Centers for Disease Control and Prevention offers practical tips for managing diabetes during illness.

The Role of the Multidisciplinary Healthcare Team

Optimal hyperglycemia prevention requires coordinated care between oncology, endocrinology, nutrition, pharmacy, and nursing. Before starting chemotherapy, patients should undergo a baseline glycemic assessment, including HbA1c, fasting glucose, and renal function. Clear glucose targets should be individualized: typically fasting 80–130 mg/dL and postprandial below 180 mg/dL, though these may be relaxed in patients with brittle diabetes or frequent hypoglycemia. Hospitals should implement standardized protocols for managing hyperglycemia in cancer patients, such as basal-bolus insulin regimens (rather than sliding scale alone) and guidelines for corticosteroid-induced hyperglycemia. Integration of diabetes technology—such as sharing CGM data via Dexcom Clarity or LibreView—allows the care team to monitor glucose trends remotely and intervene before a patient becomes symptomatic.

Conclusion

Preventing hyperglycemia during chemotherapy is a critical component of comprehensive cancer care for patients with diabetes. Through vigilant monitoring, consistent nutrition, appropriate physical activity, stress management, and careful medication adjustments, patients can maintain glycemic control and reduce the risk of treatment interruptions and complications. Blood sugar management is not an add-on; it is integral to safe and effective cancer treatment. With a dedicated healthcare team and the right tools, patients can navigate the dual challenges of diabetes and chemotherapy while preserving their quality of life and maximizing the chance of successful cancer outcomes.